Sub-$1 stocks are a different animal from the rest of the equity market — wider spreads, thinner liquidity, and single-session moves of 20% to 50% aren’t the exception, they’re the norm. Heading into Monday, August 31, 2026, a handful of names in this ultra-speculative corner of the market are carrying genuinely fresh catalysts: partnership announcements, a crypto-treasury pivot, a cobalt supply lock-in, and at least one company facing real delisting pressure. Here are 10 stocks under $1 to watch tomorrow, with the full data and the honest risks behind each one.
Market Snapshot
- Macro backdrop: Fed Chair Kevin Warsh’s hawkish Jackson Hole remarks last Friday pushed September rate-hike odds sharply higher, a dynamic that tends to hit cash-burning, speculative micro-caps hardest since higher-for-longer rates make it more expensive for these companies to raise fresh capital.
- Why sub-$1 stocks matter right now: With capital-raising conditions tightening, dilution risk is elevated across this entire list — nearly every name below has completed, or is actively pursuing, some form of share issuance in 2026.
- Liquidity warning: Bid/ask spreads on sub-$1 names can represent 5% or more of the share price on a single trade, and sub-10-cent names can see spreads of 10-30% — a hidden cost every trader on this list should factor in before placing an order.
1. Iveda Solutions, Inc. (IVDA) — $0.33 | Drone Line Launch Meets a Brutal 52-Week Range
| Metric | Value |
|---|---|
| Recent Price | $0.33 |
| Day’s Range (Aug 20) | $0.33 – $0.38 |
| 52-Week High | $2.24 |
| 52-Week Low | $0.21 |
| Market Cap | ~$4.25 million |
The Catalyst
Iveda, an AI-driven video surveillance and IoT company, has been on a partnership tear in August: it launched its IvedaAir RUAS drone line, featuring a gas-powered smart drone for public safety, maritime security, and emergency response missions, and separately announced a strategic partnership with GlobalMed — a tie-up that reportedly sent shares up 30% on the news. The company also disclosed a new partnership with Primion in late July.
Bull Case vs. Bear Case
Bull case: Multiple partnership announcements in a single month suggest real commercial momentum, and the drone line launch diversifies Iveda beyond its core video-surveillance business into a higher-growth public-safety niche.
Bear case: At a $4.25 million market cap, Iveda is about as thin and illiquid as public companies get — the stock’s 52-week range ($0.21 to $2.24) shows just how violently shares can swing in either direction on light volume.
Forecast
Watch the $0.33-$0.38 zone as near-term support; a break back toward the 52-week low of $0.21 would suggest the recent partnership news has fully faded from trader attention.
2. Liminatus Pharma, Inc. (LIMN) — $0.18 | A Cancer Biotech Pivoting Into BNB Treasury
| Metric | Value |
|---|---|
| Recent Price | $0.18 |
| Market Cap | ~$8.26 million |
| 52-Week High | $33.66 (post-reverse-split adjusted) |
| 52-Week Low | $0.1592 |
| 1-Year Performance | -97.42% |
The Catalyst
Liminatus, a pre-clinical immuno-oncology company developing a next-generation CD47 immune checkpoint inhibitor, secured $1.9 million in cash via warrant exercises this month. But the more unusual headline is strategic: Liminatus has identified BNB Coin as its primary strategic target for digital asset allocation, with stated plans to aggressively accumulate and hold up to $500 million for long-term strategic value — an extraordinarily large ambition relative to the company’s current $8.26 million market cap.
Bull Case vs. Bear Case
Bull case: If the BNB treasury strategy gains any real traction, it could re-rate the stock similarly to how Bitcoin-treasury micro-caps have traded at premiums to their underlying holdings in past cycles.
Bear case: A company with an $8.26 million market cap announcing a $500 million crypto-accumulation target is an enormous gap between ambition and current resources — and the stock is down 97.42% over the past year, reflecting a long history of dilution and cash burn in the core biotech business.
Forecast
Any concrete BNB purchase disclosure (rather than just a stated intention) would be the clearest signal of whether this pivot is real or aspirational — watch for SEC filings confirming an actual transaction.
3. Outlook Therapeutics, Inc. (OTLK) — $0.68 | An FDA Win Overshadowed by a Revenue Miss
| Metric | Value |
|---|---|
| Recent Price | $0.68 |
| Day’s Range (Aug 25) | $0.60 – $0.68 |
| 52-Week High | $3.39 |
| 52-Week Low | $0.16 |
| Market Cap | ~$164.6 million |
| Average Analyst Target | $5.40 (Strong Buy) |
The Catalyst
Outlook Therapeutics has had a genuinely eventful 2026: the company won an appeal following a formal FDA dispute resolution process for ONS-5010/LYTENAVA (bevacizumab-vikg), its ophthalmic anti-VEGF treatment for wet age-related macular degeneration, and its resubmitted BLA was subsequently accepted by the FDA. Despite that regulatory progress, the company reportedly missed revenue estimates by 99.3% in a recent quarter, and it’s now targeting a permanent J-code (the billing code that enables consistent insurance reimbursement) by April 2027.
Bull Case vs. Bear Case
Bull case: Three analysts rate the stock a “Strong Buy” with an average target of $5.40 — implying massive upside — reflecting confidence that LYTENAVA’s regulatory hurdles are largely behind it and commercial ramp is just delayed, not derailed.
Bear case: A 99.3% revenue miss is not a rounding error — it’s a signal that the commercial launch is struggling badly regardless of the regulatory wins, and the company has repeatedly turned to $5 million registered direct offerings to fund operations.
Forecast
The permanent J-code timeline (targeted for April 2027) is the structural catalyst that matters most for OTLK’s long-term reimbursement economics — watch for interim, temporary code assignments as a leading indicator before then.
4. Electra Battery Materials Corporation (ELBM) — $0.63 | A Cobalt Refinery Locking In Long-Term Supply
| Metric | Value |
|---|---|
| Recent Price | $0.63 |
| Recent Range | $0.572 – $0.6293 (mid-to-late August) |
| Analyst Target | $2.00 (H.C. Wainwright, trimmed from $2.10) |
| Sector | Cobalt/battery materials refining |
The Catalyst
Electra has strung together a genuinely dense run of operational news this month: locking in long-term cobalt supply for its Ontario refinery, advancing construction at that same Ontario cobalt sulfate refining facility, appointing Peter Rawlins as CFO, and reporting strong H1 2026 results with equity surging on a warrant revaluation. The company also highlighted how new U.S. black mass export limits could boost domestic refining economics — a policy tailwind for a company trying to build out North American battery-material supply chains.
Bull Case vs. Bear Case
Bull case: The combination of secured cobalt supply, refinery construction progress, and a friendly domestic-refining policy backdrop gives Electra a genuinely differentiated, multi-catalyst story compared to most sub-$1 names on this list.
Bear case: H.C. Wainwright trimmed its price target to $2.00 from $2.10 even while maintaining coverage, and the company has repeatedly turned to ATM offerings (including a recent $2.1 million raise) and credit-term adjustments to support government-backed financing — signs that capital remains tight.
Forecast
StockInvest.us rated ELBM a “Sell Candidate” with a technical score of -1.49 as of mid-August, even as the fundamental catalyst flow has been positive — a reminder that technical and fundamental signals can diverge sharply on thinly-traded names like this.
5. AIM ImmunoTech Inc. (AIM) — $0.28 | An Earnings Report That Could Break the Recent Uptrend
| Metric | Value |
|---|---|
| Recent Price | ~$0.271 – $0.29 |
| Earnings Date | Reported August 13, 2026 |
| Consensus EPS Estimate | -$0.17 |
| Technical Rating | Upgraded from Sell to Hold/Accumulate |
The Catalyst
AIM ImmunoTech’s stock had been on a modest uptrend into its August 13 earnings report, rising in 6 of its prior 10 sessions and up 14.62% over two weeks heading into the print, with technical models projecting a possible swing of +/- 9.20% in the first trading day after results. The stock’s technical rating was upgraded from Sell to Hold/Accumulate just days before the report — a modestly encouraging signal, though still short of an outright buy recommendation.
Bull Case vs. Bear Case
Bull case: A sell signal originally issued back in early June had already produced a 68.24% decline by early August, meaning much of the bad news may already be priced in, setting up a potential relief bounce if the earnings report avoided a major negative surprise.
Bear case: A technical upgrade from Sell to Hold is a low bar — it reflects reduced downside pressure, not a genuine bullish thesis, and the company’s consensus EPS estimate of -$0.17 reflects continued substantial losses.
Forecast
With earnings already reported August 13, the stock’s subsequent price action through the rest of August should reveal whether the pre-earnings technical upgrade was validated or reversed — worth checking the most recent trading levels before entering any position.
6. Genius Group Limited (GNS) — $0.18 | An AI Education Company With a Cash Bonus Program Still in Play
| Metric | Value |
|---|---|
| Recent Price | $0.18 |
| Day’s Range (Aug 26) | $0.18 |
| 52-Week High | $1.28 |
| 52-Week Low | $0.15 |
| Sector | AI education / digital banking |
The Catalyst
Genius Group has spent 2026 pursuing an unusually ambitious dual strategy: expanding its AI-education platform while simultaneously deploying capital from an $800 million “AI Treasury” initiative that has included pre-IPO exposure to companies like Anthropic, SpaceX, and OpenAI via the Fundrise Innovation Fund. The company previously ran a Share Loyalty Bonus Program offering cash payments per qualifying share, a mechanism designed to provide technical price support.
Bull Case vs. Bear Case
Bull case: Unaudited results earlier in the year showed revenue up sharply year-over-year alongside a swing to net operating profit, and the AI Treasury initiative gives shareholders indirect exposure to some of the most sought-after private AI companies in the world.
Bear case: A securities class action has been filed alleging investor harm, and the stock remains near its 52-week low of $0.15 despite the operating-profit swing — a sign the market remains skeptical of the broader narrative.
Forecast
With shares sitting just $0.03 above the 52-week low, this is a name where any close below $0.15 would represent a genuinely bearish technical breakdown, while a bounce off this zone would suggest the loyalty-program support level is holding.
7. Rekor Systems, Inc. (REKR) — $0.71 | A Fresh Seven-Year State Contract
| Metric | Value |
|---|---|
| Recent Price | $0.71 |
| Day’s Range (Aug 13) | $0.70 – $0.75 |
| 52-Week High | $3.42 |
| 52-Week Low | $0.55 |
| Market Cap | ~$104 million |
The Catalyst
Rekor Systems, an AI-powered roadway intelligence company, announced August 11 that it had been selected by the South Carolina Department of Transportation for a statewide contract with a seven-year term — exactly the kind of durable, recurring government revenue that distinguishes Rekor from most names on this list. This adds to Rekor’s existing $16.8 million Oklahoma District Attorneys Council contract and prior deployments with Caltrans and Texas DOT.
Bull Case vs. Bear Case
Bull case: Rekor’s Q2 2026 results showed revenue and recurring revenue growth alongside gross margin expansion and a sharply reduced adjusted EBITDA loss (down 78% year-over-year to approximately $1.3 million), and management has explicitly framed the quarter as the point where operational realignment became “clearly visible” in the financial results.
Bear case: Full-year 2025 losses still totaled $31.46 million against revenue of just $48.45 million, and the company has a history of Nasdaq bid-price compliance concerns tied to trading below $1.
Forecast
One community technical analysis flagged a 75-80% estimated probability of REKR reaching $2, citing support-zone technicals, low debt, and a tight 31-million-share float with roughly 20% short interest — a setup that could produce an outsized squeeze-driven move if a fresh catalyst emerges.
8. Milestone Scientific Inc. (MLSS) — Recent Range $0.30–$0.58 | A Medical Device Story Riding Revenue Growth
| Metric | Value |
|---|---|
| Recent Range | $0.30 – $0.58 |
| 52-Week High | $1.39 |
| 52-Week Low | $0.22 |
| Analyst Target | $1.00–$1.25 (Buy) |
The Catalyst
Milestone Scientific, maker of the CompuFlo pressure-guided injection system used in epidural, neuromodulation, and interventional pain procedures, has posted accelerating revenue growth in recent quarters — a genuinely encouraging fundamental signal for a company this small. Preliminary first-half 2026 revenue came in around $5.0 million, up 9% year-over-year, with a more recent quarter showing 21% year-over-year growth.
Bull Case vs. Bear Case
Bull case: Accelerating quarter-over-quarter revenue growth and expanding physician adoption of CompuFlo support the bullish analyst case toward the $1.00-$1.25 target range — a potential double or more from the lower end of the stock’s recent trading range.
Bear case: The company remains unprofitable with a market cap below $70 million, and continued cash burn makes further dilutive financing a real possibility that could offset fundamental progress.
Forecast
Sustained double-digit revenue growth through the back half of 2026 would likely be needed to justify the current analyst price targets — a deceleration in growth would probably trigger target cuts given how much of the bull case rests on the growth trajectory holding.
9. Synergy CHC Corp. (SNYR) — ~$0.20 | A Tiny Float With a Big Retail Win
| Metric | Value |
|---|---|
| Recent Price | ~$0.20 |
| 52-Week High | $4.00 |
| 52-Week Low | $0.19 |
| Shares Outstanding | ~11.25 million |
| Short Interest Change | +27.59% month-over-month |
The Catalyst
Synergy CHC, which markets the FOCUSfactor brain-health supplement brand along with Flat Tummy and Hand MD skincare lines, expanded FOCUSfactor’s functional beverage distribution across Canada through Walmart — a meaningful retail shelf-space win for a company of this size. With only about 11.25 million shares outstanding, this is one of the tightest floats on the entire list.
Bull Case vs. Bear Case
Bull case: The extremely thin float means even a modest sales inflection from the new Walmart Canada distribution could have an outsized effect on the share price, since there simply aren’t many shares available to absorb buying pressure.
Bear case: The stock has fallen more than 90% over the past year, and short interest recently rose 27.59% month-over-month — a sign that bearish positioning is actually increasing even as the retail-distribution news should theoretically be a positive catalyst.
Forecast
Watch same-store sell-through data from the new Canadian distribution channel as the clearest near-term indicator of whether the brand-expansion thesis can overcome the building short interest.
10. Nano-X Imaging Ltd. (NNOX) — ~$1.06–$1.08 | Hovering Right at the Dollar Threshold Amid a Going-Concern Warning
| Metric | Value |
|---|---|
| Recent Price | ~$1.06–$1.08 |
| Day’s Range | $1.04 – $1.11 |
| 52-Week High | $4.88 |
| 52-Week Low | $0.73 |
| Average Analyst Target | $5.80 (Strong Buy) |
The Catalyst
Nano-X Imaging is included here specifically because it’s trading right at the sub-$1 threshold, and the news flow around it has been genuinely alarming for a company still technically rated “Strong Buy” by its three covering analysts. The company issued preliminary Q2 2026 results alongside going-concern doubts tied to a broader cash crunch, priced an $8 million registered direct offering while conducting a broad impairment review, and set a September 17, 2026 shareholder meeting specifically to approve a share capital increase — typically a precursor to further dilutive financing.
Bull Case vs. Bear Case
Bull case: The average analyst price target of $5.80 implies more than 360% upside, reflecting continued institutional belief in the company’s FDA-cleared Nanox.ARC multisource imaging system and its expanding teleradiology and Health IT revenue streams.
Bear case: Going-concern language, an active impairment review, a pending shareholder vote on increasing share capital, and multiple securities class actions (with an August 11 lead plaintiff deadline already passed) collectively represent one of the more serious risk profiles on this entire list — this is a name where the fundamental story and the balance-sheet reality have diverged sharply.
Forecast
The September 17 shareholder meeting is the single most important date to watch — approval of a share capital increase would likely precede additional dilutive offerings, while any surprise strategic alternative (a partnership, licensing deal, or acquisition interest) could meaningfully change the trajectory before then.
Sector Sentiment Snapshot
This list splits fairly evenly between two very different stories: companies with genuine, verifiable operational momentum (Electra Battery Materials’ refinery progress, Rekor’s new state contract, Milestone Scientific’s revenue acceleration) and companies where speculative catalysts — a crypto-treasury pivot, a cash bonus program, a going-concern-adjacent turnaround bet — are doing most of the work. For sub-$1 stocks specifically, dilution risk should be treated as a near-certainty rather than a tail risk across nearly every name on this list, given how consistently these companies have turned to registered direct offerings, ATM programs, and warrant exercises to fund operations throughout 2026.
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and stocks trading under $1 carry substantially elevated risk, including wide bid/ask spreads, thin liquidity, dilution, and delisting risk. Support and resistance levels cited are technical analysis estimates based on historical price data and do not guarantee future price behaviour. Always complete independent due diligence prior to executing equity trades.
About The Author
